Anti-inflammatory drug shows promise for frailty in older adults

NCT ID NCT05727384

Completed Symptom relief Sponsor: Anne B. Newman Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether clazakizumab, an anti-inflammatory drug, could improve walking speed and reduce disability in older adults with frailty. 29 participants aged 70 and older received either the drug or a placebo every 4 weeks for 24 weeks. Researchers measured walking speed, physical function, and blood markers of inflammation to see if the drug made a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clazakizumab
What this could lead to: If it works, this could point toward a treatment that helps older adults with frailty walk faster and feel stronger by reducing inflammation.
What could go wrong: This is a small, early Phase 2 trial with only 29 participants, so results may not apply to everyone. The drug may not improve mobility or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAILTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAILTY INFLAMMATION

Contacts and locations

Locations

University of Pittsburgh, Health Studies Research Center

Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.